This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Novartis to License VYGR's Capsid for Gene Therapy in Neurology
by Zacks Equity Research
NVS has decided to license a novel capsid generated from Voyager's TRACER platform for use in a gene therapy program against an undisclosed rare neurologic disease target.
Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 52.63% and 156.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 54.55% and 88.87%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 21.48% and 85.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 26.17% and 10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
by Zacks Equity Research
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat
by Zacks Equity Research
Puma Biotechnology (PBYI) reports narrower-than-expected first-quarter 2024 loss. The company maintains its revenue guidance for 2024.
Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Corcept (CORT) beats on both earnings and sales in the first quarter of 2024. The company increases revenue guidance for 2024.
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.
Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates
by Zacks Equity Research
Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.
Repligen (RGEN) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Repligen's (RGEN) first-quarter 2024 earnings miss estimates while revenues beat the same.
Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amarin (AMRN) posts better-than-expected first-quarter 2024 results. Vascepa's sales in the United States continue to be hurt by generic competition.
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
by Zacks Equity Research
Exelixis (EXEL) misses on earnings and sales in the first quarter. Its shares are trading down in response to the results.
New Strong Buy Stocks for May 1st
by Zacks Equity Research
EC, SKX, BVN, VYGR and WU have been added to the Zacks Rank #1 (Strong Buy) List on May 1, 2023.
Novavax (NVAX) Surges 8.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More
by Zacks Equity Research
Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.
Voyager (VYGR) Gains on Gene Therapy Deal With Novartis
by Zacks Equity Research
Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.
Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 13.56% and 142.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Moves 7.9% Higher: Will This Strength Last?
by Zacks Equity Research
Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Voyager Therapeutics (VYGR) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 1,860% and 51.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Surges 11.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Lumos Pharma (LUMO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lumos (LUMO) delivered earnings and revenue surprises of 20.54% and 126.56%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Seattle Genetics (SGEN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) delivered earnings and revenue surprises of -13.41% and 0.23%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Morphic Holding, Inc. (MORF) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -5.88% and 78.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -7.02% and 112.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?